Dr. John M. Rutkowski, M.D.
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 789
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: State University of New York at Buffalo School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
NY license 264603
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Kaleida Health Buffalo, NY
- Sisters of Charity Hospital Buffalo, NY
- Kenmore Mercy Hospital Kenmore, NY
- Mount St. Mary's Hospital & Health Center Lewiston, NY
- Niagara Falls Memorial Medical Center Niagara Falls, NY
Medical groups
- Kaleida Health (236 clinicians)
- Great Lakes Physician PC (66 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 789
- Services billed
- 9,396
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Automated urinalysis test | 829 | 568 |
| Leuprolide injectable, camcevi, 1 mg | 630 | 14 |
| Established patient office or other outpatient visit, 30-39 minutes | 596 | 424 |
| Established patient office or other outpatient visit, 20-29 minutes | 354 | 307 |
| Ultrasound measurement of bladder capacity after voiding | 234 | 197 |
| Insertion of needle into vein for collection of blood sample | 220 | 186 |
| Psa (prostate specific antigen) measurement, total | 131 | 120 |
| Diagnostic exam of bladder and urethra using an endoscope | 94 | 85 |
| Ct guidance for insertion of radiation therapy fields | 90 | 35 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 86 | 32 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xtandi (enzalutamide) | 633 |
| Tamsulosin Hcl Other prescribers in Sanborn, NY | 599 |
| Prednisone Other prescribers in Sanborn, NY | 417 |
| Abiraterone Acetate | 400 |
| Finasteride Other prescribers in Sanborn, NY | 355 |
| Myrbetriq (mirabegron) Other prescribers in Sanborn, NY | 268 |
| Nubeqa (darolutamide) | 244 |
| Alfuzosin Hcl Er (alfuzosin hcl) Other prescribers in Sanborn, NY | 84 |
| Ciprofloxacin Hcl Other prescribers in Sanborn, NY | 74 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Sanborn, NY | 73 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 33 payments worth $989 in total to this clinician.
| Janssen Biotech, Inc. | $314 |
|---|---|
| Astellas Pharma US Inc | $254 |
| Boston Scientific Corporation | $149 |
| Bayer HealthCare Pharmaceuticals Inc. | $119 |
| Sumitomo Pharma America, Inc. | $35.95 |
| Acera Surgical, Inc. | $29.61 |
| Calyxo, Inc. | $25.37 |
| Pfizer Inc. | $19.58 |
| Food and Beverage | $825 |
|---|---|
| Education | $164 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Mar 28, 2025 | Education in-kind | $89.00 |
| Astellas Pharma US Inc Apr 21, 2025 | Education in-kind | $74.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $76,225 in research payments for these studies, mostly to the institutions running them.
- Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06510374 - A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Ferring Pharmaceuticals As · Recruiting · NCT06545955 - A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.